Protagonist Therapeutics, Inc.
PTGX
$86.63
$1.982.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -15.04% | -80.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.04% | -80.42% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -15.04% | -80.42% | |||
| SG&A Expenses | 5.49% | -10.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.45% | -0.09% | |||
| Operating Income | -10.42% | -117.72% | |||
| Income Before Tax | -13.70% | -196.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -13.14% | -198.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.14% | -198.34% | |||
| EBIT | -10.42% | -117.72% | |||
| EBITDA | -10.36% | -118.85% | |||
| EPS Basic | -12.68% | -195.79% | |||
| Normalized Basic EPS | -13.22% | -194.30% | |||
| EPS Diluted | -12.73% | -189.47% | |||
| Normalized Diluted EPS | -13.22% | -194.30% | |||
| Average Basic Shares Outstanding | 0.41% | 0.87% | |||
| Average Diluted Shares Outstanding | 0.41% | 0.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||